<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AVONEX- interferon beta-1aÂ 
			Â </strong><br>Biogen Idec MA Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use AVONEX safely and effectively. See full prescribing information for AVONEX. <br>AVONEX (interferon beta-1a) injection, for intramuscular injection <br>Initial U.S. Approval: 1996
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">AVONEX is an interferon beta indicated for the treatment of patients with relapsing forms of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> to slow the accumulation of physical <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> and decrease the frequency of clinical exacerbations. Patients with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>. (<a href="#s1">1</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>For intramuscular use only (<a href="#s3">2.1</a>)
</li>
<li>Recommended dose: 30 micrograms once a week (<a href="#s3">2.1</a>)
</li>
<li>AVONEX may be titrated, starting with 7.5 micrograms for first week, to reduce flu-like symptoms (<a href="#s3">2.1</a>)
</li>
<li>Increase dose by 7.5 micrograms each week for next 3 weeks until recommended dose of 30 micrograms (<a href="#s3">2.1</a>)
</li>
<li>See patient instructions for use for complete administration instructions (<a href="#s4">2.2</a>)
</li>
<li>Perform first injection under the supervision of an appropriately qualified health care professional (<a href="#s4">2.2</a>)
</li>
<li>Analgesics and/or antipyretics on treatment days may help ameliorate flu-like symptoms (<a href="#s5">2.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>For Injection: 30 micrograms lyophilized powder in a single-use vial (<a href="#s6">3</a>)
</li>
<li>Injection: 30 micrograms per 0.5 mL solution in single-use prefilled syringe (<a href="#s6">3</a>)
</li>
<li>Injection: Single-use prefilled autoinjector containing 0.5 mL solution with 30 mcg (<a href="#s6">3</a>)
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to natural or recombinant interferon beta, albumin or any other component of the formulation (<a href="#s7">4</a>)
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic Disorders</span>: advise patients to immediately report any symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, and/or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>; consider discontinuation of AVONEX if <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> occurs (<a href="#s9">5.1</a>)
</li>
<li>Hepatic Injury: monitor liver function tests; monitor patients for signs and symptoms of hepatic injury; consider discontinuation of AVONEX if hepatic injury occurs (<a href="#s10">5.2</a>, <a href="#s16">5.8</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and Other Allergic-Reactions: Discontinue if occurs (<a href="#s11">5.3</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>: monitor patients with pre-existing significant cardiac disease for worsening of cardiac symptoms (<a href="#s12">5.4</a>)
</li>
<li>Decreased Peripheral Blood Counts: monitor complete blood count (<a href="#s13">5.5</a>, <a href="#s16">5.8</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune Disorders</span>: consider discontinuation of AVONEX if new <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorder</span> occurs (<a href="#s15">5.7</a>, <a href="#s16">5.8</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (at least 5% more frequent on AVONEX than on placebo) were flu-like symptoms including <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>. (<a href="#s18">6.1</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Biogen Idec at 1-800-456-2255 or FDA at 1-800-FDA-1088 or </span><span class="Bold Italics Underline">www.fda.gov/medwatch</span>.
 </p>
</div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>Pregnancy: Based on animal data, may cause fetal harm (<a href="#s22">8.1</a>)
</li></ul></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 3/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Information
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Important Administration Instructions (All Dosage Forms)
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Premedication for Flu-like Symptoms
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic Disorders</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Hepatic Injury
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and Other Allergic-Reactions
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Decreased Peripheral Blood Counts
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune Disorders</span>
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Laboratory Tests
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION
</a></h1>
<h2><a href="#section-8.1" class="toc">11.1 AVONEX Lyophilized Powder Vial
</a></h2>
<h2><a href="#section-8.2" class="toc">11.2 AVONEX Single-Use Prefilled Syringe
</a></h2>
<h2><a href="#section-8.3" class="toc">11.3 AVONEX PEN Single-Use Prefilled Autoinjector
</a></h2>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-9.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-9.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility
</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES
</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h2><a href="#section-12.1" class="toc">16.1 AVONEX Lyophilized Powder Vial
</a></h2>
<h2><a href="#section-12.2" class="toc">16.2 AVONEX Single-Use Prefilled Syringe
</a></h2>
<h2><a href="#section-12.3" class="toc">16.3 AVONEX PEN Single-Use Prefilled Autoinjector
</a></h2>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-13.1" class="toc">17.1 Instruction on Self-injection Technique and Procedures
</a></h2>
<h2><a href="#section-13.2" class="toc">17.2 Pregnancy
</a></h2>
<h2><a href="#section-13.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>
</a></h2>
<h2><a href="#section-13.4" class="toc">17.4 Liver Disease
</a></h2>
<h2><a href="#section-13.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>
</a></h2>
<h2><a href="#section-13.6" class="toc">17.6 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>
</a></h2>
<h2><a href="#section-13.7" class="toc">17.7 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</a></h2>
<h2><a href="#section-13.8" class="toc">17.8 Flu-like Symptoms
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First">AVONEX (interferon beta-1a) is indicated for the treatment of patients with relapsing forms of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> to slow the accumulation of physical <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> and decrease the frequency of clinical exacerbations. Patients with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Information
</h2>
<p class="First">AVONEX is administered intramuscularly.
</p>
<p>The recommended dose is 30 micrograms once a week. To reduce the incidence and severity of flu-like symptoms that may occur when initiating AVONEX therapy at a dose of 30 micrograms, AVONEX may be started at a dose of 7.5 micrograms and the dose may be increased by 7.5 micrograms each week for the next three weeks until the recommended dose of 30 micrograms is achieved (see <a href="#t1">Table 1</a>). An AVOSTARTGRIP kit containing 3 titration devices can be used for titration and is to be used only with AVONEX Prefilled Syringes.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Schedule for Dose Titration
</span></caption>
<col align="left" width="24.433%">
<col align="left" width="31.433%">
<col align="left" width="44.133%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">1</span>Dosed once a week, intramuscularly
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="left" valign="top">AVONEX Dose<span class="Sup">1</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">Recommended Dose
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Week 1
</td>
<td class="Botrule Rrule" align="left" valign="top">7.5 micrograms
</td>
<td class="Botrule Rrule" align="left" valign="top">1/4 dose
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Week 2
</td>
<td class="Botrule Rrule" align="left" valign="top">15 micrograms
</td>
<td class="Botrule Rrule" align="left" valign="top">1/2 dose
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Week 3
</td>
<td class="Botrule Rrule" align="left" valign="top">22.5 micrograms
</td>
<td class="Botrule Rrule" align="left" valign="top">3/4 dose
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Week 4+
</td>
<td class="Botrule Rrule" align="left" valign="top">30 micrograms
</td>
<td class="Botrule Rrule" align="left" valign="top">full dose
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Important Administration Instructions (All Dosage Forms)
</h2>
<p class="First">All AVONEX dosage forms are single-use (injection of reconstituted solution, prefilled syringe, and prefilled autoinjector). See Patient's Instructions for Use for complete administration instructions.
</p>
<p>The first AVONEX injection should be performed under the supervision of an appropriately qualified health care professional. If patients or caregivers are to administer AVONEX, train them in the proper intramuscular injection technique and assess their ability to inject intramuscularly to ensure the proper administration of AVONEX.
</p>
<p>Advise patients and caregivers to:
</p>
<ul class="Disc">
<li>rotate sites for intramuscular injections with each injection to minimize the likelihood of <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>
</li>
<li>NOT inject into an area of the body where the skin is irritated, reddened, bruised, infected or scarred in any way
</li>
<li>Check the injection site after 2 hours for <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>
</li>
<li>Contact their doctor or nurse if they have a <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> and it does not clear up in a few days
</li>
</ul>
<p>A 25 gauge, 1â€? needle for intramuscular injection with AVONEX prefilled syringe or injection of reconstituted solution may be substituted for the 23 gauge, 1 Â¼â€? needle by the healthcare provider, if deemed appropriate. A 25 gauge, 5/8â€? needle specific to the prefilled autoinjector is supplied with the AVONEX PEN Administration Dose Pack. <span class="Bold">DO NOT</span> use any other needle with the autoinjector.
</p>
<p>Use safe disposal procedures for needles and syringes. Do not re-use needles, syringes, prefilled syringes, or autoinjectors. Following the administration of each titrated dose, discard any remaining product.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Premedication for Flu-like Symptoms
</h2>
<p class="First">Concurrent use of analgesics and/or antipyretics on treatment days may help ameliorate flu-like symptoms associated with AVONEX use.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s6"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<ul class="Disc">
<li>For injection: 30 micrograms lyophilized powder in a single-use vial
</li>
<li>Injection: 30 micrograms per 0.5 mL solution in a single-use prefilled syringe
</li>
<li>Injection: 30 micrograms per 0.5 mL solution in a single-use prefilled autoinjector
</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">AVONEX is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to natural or recombinant interferon beta, or any other component of the formulation [see <span class="Italics">Warnings and Precautions (<a href="#s11">5.3</a>)</span>].
</p>
<p>The lyophilized vial formulation of AVONEX is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to albumin (human).
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic Disorders</span>
</h2>
<p class="First">Patients treated with AVONEX and their caregivers should be advised to report immediately any symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, and/or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> to their prescribing physicians. If a patient develops <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other severe <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>, cessation of AVONEX therapy should be considered.
</p>
<p><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> have been reported to occur with increased frequency in patients receiving AVONEX. In Study 1, the incidence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> was similar in placebo-treated and in AVONEX-treated patients, but <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal tendency</span> was seen more frequently in AVONEX-treated patients (4% in AVONEX group vs. 1% in placebo group). In Study 2, there was a greater incidence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in AVONEX-treated patients than in placebo-treated patients (20% in AVONEX group vs. 13% in placebo group) [see <span class="Italics">Clinical Studies (<a href="#s40">14</a>)</span>].
</p>
<p>Additionally, there have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, and/or development of new or worsening of other pre-existing psychiatric disorders, including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. For some of these patients, symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> improved upon cessation of AVONEX.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Hepatic Injury
</h2>
<p class="First">Severe hepatic injury, including cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, has been reported rarely in patients taking AVONEX. Asymptomatic elevation of hepatic transaminases has also been reported, and in some patients has recurred upon rechallenge with AVONEX. In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury. The potential risk of AVONEX used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered prior to starting AVONEX, or before starting hepatotoxic drugs. Patients should be monitored for signs of hepatic injury [see <span class="Italics">Warnings and Precautions (<a href="#s16">5.8</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and Other Allergic-Reactions
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported as a rare complication of AVONEX use. Other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have included <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, orolingual <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. Discontinue AVONEX if <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> occur.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>
</h2>
<p class="First">Patients with pre-existing <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> should be monitored for worsening of their cardiac condition during initiation of and continued treatment with AVONEX. While beta interferons do not have any known direct cardiac toxicity, during the post-marketing period cases of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> have been reported in patients without known predisposition to these events, and without other etiologies being established. In some cases, these events have been temporally related to the administration of AVONEX. In some of these instances recurrence upon rechallenge was observed.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Decreased Peripheral Blood Counts
</h2>
<p class="First">Decreased peripheral blood counts in all cell lines, including rare <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, have been reported from postmarketing experience in AVONEX-treated patients [see <span class="Italics">Adverse Reactions (<a href="#s20">6.2</a>)</span>]. In some cases, platelet counts were below 10,000/microliter. Some cases recurred with rechallenge [see <span class="Italics">Adverse Reactions (<a href="#s20">6.2</a>)</span>]. Patients should be monitored for symptoms or signs of decreased blood counts.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been temporally associated with the use of beta interferons in clinical trials and postmarketing safety surveillance. In the two placebo-controlled studies in <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> (Studies 1 and 2), 4 patients receiving AVONEX experienced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, while no <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occurred in the placebo group [see <span class="Italics">Clinical Studies (<a href="#s40">14</a>)</span>]. Three of these 4 patients had no prior history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> [see <span class="Italics">Adverse Reactions (<a href="#s18">6.1</a>)</span>]. It is not known whether these events were related to the effects of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> alone, to AVONEX, or to a combination of both.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune Disorders</span>
</h2>
<p class="First">Post-marketing reports of <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorders</span> of multiple target organs in AVONEX-treated patients included <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenia</span>, hyper- and <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and rare cases of <span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">autoimmune hepatitis</span>. If AVONEX-treated patients develop a new <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorder</span>, consider stopping the therapy.
</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s16"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Laboratory Tests
</h2>
<p class="First">In addition to those laboratory tests normally required for monitoring patients with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, complete blood and differential white blood cell counts, platelet counts, and blood chemistries, including liver function tests, are recommended during AVONEX therapy [see <span class="Italics">Warnings and Precautions (<a href="#s10">5.2</a>, <a href="#s13">5.5</a>, <a href="#s15">5.7</a>)</span>]. Patients with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> may require more intensive monitoring of complete blood cell counts, with differential and platelet counts. Thyroid function should be monitored periodically. If patients have or develop symptoms of thyroid dysfunction (hypo- or <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>), <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">thyroid function tests</span> should be performed according to standard medical practice.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s17"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">The following serious adverse reactions are discussed in more detail in other sections of labeling:
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic Disorders</span> [see <span class="Italics">Warnings and Precautions (<a href="#s9">5.1</a>)</span>]
</li>
<li>Hepatic Injury [see <span class="Italics">Warnings and Precautions (<a href="#s10">5.2</a>)</span>]
</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and Other Allergic-Reactions [see <span class="Italics">Warnings and Precautions (<a href="#s11">5.3</a>)</span>]
</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> [see <span class="Italics">Warnings and Precautions (<a href="#s12">5.4</a>)</span>]
</li>
<li>Decreased Peripheral Blood Counts [see <span class="Italics">Warnings and Precautions (<a href="#s13">5.5</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> [see <span class="Italics">Warnings and Precautions (<a href="#s14">5.6</a>)</span>]
</li>
<li><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune Disorders</span> [see <span class="Italics">Warnings and Precautions (<a href="#s15">5.7</a>)</span>]
</li>
<li>Laboratory Tests [<span class="Italics">see Warnings and Precautions</span> (<a href="#s16">5.8</a>)]
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of AVONEX cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice.
</p>
<p>Among 351 patients with relapsing forms of MS treated with AVONEX 30 micrograms (including 319 patients treated for 6 months and 288 patients treated for greater than one year) the most commonly reported adverse reactions (at least 5% more frequent on AVONEX than on placebo) were flu-like symptoms. Symptoms can include <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> occurring within hours to days following an injection. Most people who take AVONEX have flu-like symptoms early during the course of therapy. Usually, these symptoms last for a day after the injection. For many people, these symptoms lessen or go away over time. The most frequently reported adverse reactions resulting in clinical intervention (for example, discontinuation of AVONEX or the need for concomitant medication to treat an adverse reaction symptom) were flu-like symptoms and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.
</p>
<p><a href="#t2">Table 2</a> enumerates adverse reactions that occurred with AVONEX-treated patients at an incidence of at least 2% more than that observed in the placebo-treated patients in the pooled placebo-controlled studies in patients with relapsing forms of MS [see <span class="Italics">Clinical Studies (<a href="#s40">14</a>)</span>].
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2 Adverse Reactions in the Placebo-Controlled Studies
</span></caption>
<col align="left" width="58.780%">
<col align="left" width="21.626%">
<col align="left" width="19.593%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top">Placebo
</td>
<td class="Toprule" align="left" valign="top">AVONEX
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Adverse Reaction
</td>
<td class="Botrule" align="left" valign="top">(N = 333)
</td>
<td class="Botrule" align="left" valign="top">(N = 351)
</td>
</tr>
<tr>
<td align="left" valign="top">Body as a Whole
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td align="left" valign="top">55%
</td>
<td align="left" valign="top">58%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â Flu-like symptoms (otherwise unspecified)
</td>
<td align="left" valign="top">29%
</td>
<td align="left" valign="top">49%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>
</td>
<td align="left" valign="top">21%
</td>
<td align="left" valign="top">23%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>
</td>
<td align="left" valign="top">18%
</td>
<td align="left" valign="top">24%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>
</td>
<td align="left" valign="top">9%
</td>
<td align="left" valign="top">20%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>
</td>
<td align="left" valign="top">5%
</td>
<td align="left" valign="top">19%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>
</td>
<td align="left" valign="top">6%
</td>
<td align="left" valign="top">8%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span>
</td>
<td align="left" valign="top">6%
</td>
<td align="left" valign="top">8%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>
</td>
<td align="left" valign="top">4%
</td>
<td align="left" valign="top">7%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">Injection site inflammation</span>
</td>
<td align="left" valign="top">2%
</td>
<td align="left" valign="top">6%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>
</td>
<td align="left" valign="top">2%
</td>
<td align="left" valign="top">5%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span>
</td>
<td align="left" valign="top">1%
</td>
<td align="left" valign="top">3%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">Toothache</span>
</td>
<td align="left" valign="top">1%
</td>
<td align="left" valign="top">3%
</td>
</tr>
<tr>
<td align="left" valign="top">Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Nervous System
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>
</td>
<td align="left" valign="top">14%
</td>
<td align="left" valign="top">18%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td align="left" valign="top">12%
</td>
<td align="left" valign="top">14%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Respiratory System
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span>
</td>
<td align="left" valign="top">12%
</td>
<td align="left" valign="top">14%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>
</td>
<td align="left" valign="top">12%
</td>
<td align="left" valign="top">14%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span>
</td>
<td align="left" valign="top">5%
</td>
<td align="left" valign="top">8%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Digestive System
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td align="left" valign="top">19%
</td>
<td align="left" valign="top">23%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Musculoskeletal System
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>
</td>
<td align="left" valign="top">22%
</td>
<td align="left" valign="top">29%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>
</td>
<td align="left" valign="top">6%
</td>
<td align="left" valign="top">9%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Urogenital
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span>
</td>
<td align="left" valign="top">15%
</td>
<td align="left" valign="top">17%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4042234" conceptname="Abnormal urinalysis">Urine constituents abnormal</span>
</td>
<td align="left" valign="top">0%
</td>
<td align="left" valign="top">3%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Skin and Appendages
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>
</td>
<td align="left" valign="top">2%
</td>
<td align="left" valign="top">4%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Special Senses
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorder</span>
</td>
<td align="left" valign="top">2%
</td>
<td align="left" valign="top">4%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Hemic and Lymphatic System
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4316205" conceptname="Injection site hemorrhage">Injection site ecchymosis</span>
</td>
<td align="left" valign="top">4%
</td>
<td align="left" valign="top">6%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>
</td>
<td align="left" valign="top">1%
</td>
<td align="left" valign="top">4%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Cardiovascular System
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span>
</td>
<td align="left" valign="top">3%
</td>
<td align="left" valign="top">5%
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â Vasodilation
</td>
<td align="left" valign="top">0%
</td>
<td align="left" valign="top">2%
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Â  Â  Â 
</td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold Italics Underline">Immunogenicity</span></p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have occurred in AVONEX-treated patients [see <span class="Italics">Warnings and Precautions (<a href="#s11">5.3</a>)</span>]. As with all therapeutic proteins, there is a potential for immunogenicity. In studies assessing immunogenicity in <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> patients administered AVONEX for at least 1 year, 5% (21 of 390 patients) showed the presence of neutralizing antibodies at one or more times.
</p>
<p>These data reflect the percentage of patients whose test results were considered positive for antibodies to AVONEX using a two-tiered assay (ELISA binding assay followed by an antiviral cytopathic effect assay), and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of neutralizing activity in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to AVONEX with the incidence of antibodies to other products may be misleading.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<p class="First">The following additional adverse reactions have been identified during post-approval use of AVONEX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">Menorrhagia</span> and <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (including <span class="product-label-link" type="condition" conceptid="4196499" conceptname="Vesicular eruption">vesicular rash</span>)
</li>
<li>Rare cases of <span class="product-label-link" type="condition" conceptid="4317273" conceptname="Injection site abscess">injection site abscess</span> or <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span> requiring <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s21"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s22"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Category C:</span> There are no adequate and well-controlled studies in pregnant women. AVONEX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
<p>In pregnant monkeys given interferon beta at 100 times the recommended weekly human dose (based upon a body surface area [mg/m<span class="Sup">2</span>] comparison), no teratogenic or other adverse effects on fetal development were observed. Abortifacient activity was evident following 3 to 5 doses at this level. No abortifacient effects were observed in monkeys treated at 2 times the recommended weekly human dose (based upon mg/m<span class="Sup">2</span>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s24"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">It is not known whether AVONEX is excreted in human milk.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s25"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s26"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">Clinical studies of AVONEX did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s27"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">AVONEX is a 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of AVONEX is identical to that of natural human interferon beta.
</p>
<p>Using the World Health Organization (WHO) International Standard for Interferon, AVONEX has a specific activity of approximately 200 million international units of antiviral activity per mg of interferon beta-1a determined specifically by an <span class="Italics">in vitro</span> cytopathic effect bioassay using lung carcinoma cells (A549) and Encephalomyocarditis virus (ECM). AVONEX 30 micrograms contains approximately 6 million international units of antiviral activity using this method. The activity against other standards is not known. Comparison of the activity of AVONEX with other interferon betas is not appropriate, because of differences in the reference standards and assays used to measure activity.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-8.1"></a><p></p>
<h2>11.1 AVONEX Lyophilized Powder Vial
</h2>
<p class="First">A vial of AVONEX is a sterile, white to off-white lyophilized powder for intramuscular injection after reconstitution with supplied diluent (Sterile Water for Injection, USP). Each vial of reconstituted AVONEX contains 30 micrograms of interferon beta-1a; 15 mg Albumin (Human), USP; 5.8 mg Sodium Chloride, USP; 5.7 mg Dibasic Sodium Phosphate, USP; and 1.2 mg Monobasic Sodium Phosphate, USP, in 1.0 mL at a pH of approximately 7.3.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-8.2"></a><p></p>
<h2>11.2 AVONEX Single-Use Prefilled Syringe
</h2>
<p class="First">A prefilled syringe of AVONEX is a sterile liquid for intramuscular injection. Each 0.5 mL (30 microgram dose) of AVONEX in a prefilled glass syringe contains 30 micrograms of interferon beta-1a, 0.79 mg Sodium Acetate Trihydrate, USP; 0.25 mg Glacial Acetic Acid, USP; 15.8 mg Arginine Hydrochloride, USP; and 0.025 mg Polysorbate 20 in Water for Injection, USP at a pH of approximately 4.8.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-8.3"></a><p></p>
<h2>11.3 AVONEX PEN Single-Use Prefilled Autoinjector
</h2>
<p class="First">AVONEX PEN is a sterile liquid for intramuscular injection in a prefilled glass syringe surrounded by an autoinjector. Each 0.5 mL (30 microgram dose) in the AVONEX PEN contains 30 micrograms of interferon beta-1a, 0.79 mg Sodium Acetate Trihydrate, USP; 0.25 mg Glacial Acetic Acid, USP; 15.8 mg Arginine Hydrochloride, USP; and 0.025 mg Polysorbate 20 in Water for Injection, USP at a pH of approximately 4.8.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s31"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s32"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">The mechanism of action by which AVONEX exerts its effects in patients with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> is unknown.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s33"></a><a name="section-9.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<p class="First">Interferons (IFNs) are a family of naturally occurring proteins, produced by eukaryotic cells in response to <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span> and other biologic agents. Three major types of interferons have been defined: type I (IFN-alpha, beta, epsilon, kappa and omega), type II (IFN gamma) and type III (IFN-lambda). Interferon-beta is a member of the type I subset of interferons. The type I interferons have considerably overlapping but also distinct biologic activities. The bioactivities of all IFNs, including IFN-beta, are induced via their binding to specific receptors on the membranes of human cells. Differences in the bioactivites induced by the three major subtypes of IFNs likely reflect differences in the signal transduction pathways induced by signaling through their cognate receptors.
</p>
<p>Interferon beta exerts its biological effects by binding to specific receptors on the surface of human cells. This binding initiates a complex cascade of intracellular events that leads to the expression of numerous interferon-induced gene products and markers. These include 2', 5'-oligoadenylate synthetase, Î²<span class="Sub">2</span>-microglobulin, and neopterin. These products have been measured in the serum and cellular fractions of blood collected from patients treated with AVONEX.
</p>
<p>Clinical studies conducted in <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> patients showed that interleukin 10 (IL-10) levels in cerebrospinal fluid were increased in patients treated with AVONEX compared to placebo. Serum IL-10 levels maximally were increased by 48 hours after intramuscular injection of AVONEX and remained elevated for 1 week. However, no relationship has been established between absolute levels of IL-10 and clinical outcome in <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s34"></a><a name="section-9.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First">Pharmacokinetics of AVONEX in <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> patients have not been evaluated. The pharmacokinetic and pharmacodynamic profiles of AVONEX in healthy subjects following doses of 30 micrograms through 75 micrograms have been investigated. Serum levels of AVONEX as measured by antiviral activity are slightly above detectable limits following a 30 microgram intramuscular dose, and increase with higher doses.
</p>
<p>After an intramuscular dose, serum levels of AVONEX typically peak between 3 and 15 hours and then decline at a rate consistent with a 10 hour elimination half-life. Serum levels of AVONEX may be sustained after intramuscular administration due to prolonged absorption from the intramuscular site. Systemic exposure, as determined by AUC and C<span class="Sub">max</span> values, is greater following intramuscular than subcutaneous (SC) administration.
</p>
<p>Subcutaneous administration of AVONEX should not be substituted for intramuscular administration. Subcutaneous and intramuscular administration have been observed to have non-equivalent pharmacokinetic and pharmacodynamic parameters following administration to healthy volunteers.
</p>
<p>Biological response markers (e.g., neopterin and Î²<span class="Sub">2</span>-microglobulin) are induced by AVONEX following parenteral doses of 15 micrograms through 75 micrograms in healthy subjects and treated patients. Biological response marker levels increase within 12 hours of dosing and remain elevated for at least 4 days. Peak biological response marker levels are typically observed 48 hours after dosing. The relationship of serum AVONEX levels or levels of these induced biological response markers to the mechanisms by which AVONEX exerts its effects in <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> is unknown.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s35"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s36"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-10.1.1"></a><p></p>
<p class="First"><span class="Italics">Carcinogenesis:</span> The carcinogenic potential of AVONEX has not been tested in animals.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-10.1.2"></a><p></p>
<p class="First"><span class="Italics">Mutagenesis:</span> Interferon beta was not mutagenic when tested in an <span class="Italics">in vitro</span> bacterial reverse mutation (Ames) test or in an <span class="Italics">in vitro</span> cytogenetic assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-10.1.3"></a><p></p>
<p class="First"><span class="Italics">Impairment of Fertility:</span> In monkeys administered interferon beta by subcutaneous injection (8 to 15 doses of 1.25 mcg/kg or 50 mcg/kg) over the course of one menstrual cycle, menstrual irregularities, <span class="product-label-link" type="condition" conceptid="4144685" conceptname="Anovulation">anovulation</span>, and decreased serum progesterone levels were observed at the higher dose. These effects were reversible after discontinuation of drug. The no-effect dose (1.25 mcg/kg) is approximately 2 times the recommended weekly dose in humans (30 mcg) on a mg/m<span class="Sup">2</span> basis.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s40"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First">The clinical effects of AVONEX in patients with relapsing forms of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> (MS) were studied in two randomized, multicenter, double-blind, placebo-controlled studies in patients with MS (Studies 1 and 2). Safety and efficacy of treatment with AVONEX beyond 3 years is not known.
</p>
<p>In Study 1, 301 patients received either 30 micrograms of AVONEX (n=158) or placebo (n=143) by intramuscular injection once weekly. Patients received injections for up to 2 years, and continued to be followed until study completion. Two hundred eighty-two patients completed 1 year on study, and 172 patients completed 2 years on study. There were 144 patients treated with AVONEX for more than 1 year, 115 patients for more than 18 months and 82 patients for 2 years.
</p>
<p>All patients had a definite diagnosis of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> of at least 1 year duration and had at least 2 exacerbations in the 3 years prior to study entry (or 1 per year if the duration of disease was less than 3 years). At entry, study participants were without exacerbation during the prior 2 months and had Kurtzke Expanded <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Status Scale (EDSS<span class="Sup">3</span>) scores ranging from 1.0 to 3.5. The EDSS is a scale that quantifies <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> in patients with MS and ranges from 0 (normal neurologic exam) to 10 (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to MS). Patients with chronic progressive <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> were excluded from this study.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-11.1"></a><p></p>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span></span></p>
<p>The primary outcome assessment was time to progression in <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>, measured as an increase in the EDSS score of at least 1 point that was sustained for at least 6 months. An increase in EDSS score reflects accumulation of <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. This endpoint was used to help distinguish permanent increase in <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> from a transient increase due to an exacerbation.
</p>
<p>As shown in <a href="#fig1">Figure 1</a>, the time to onset of sustained progression in <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> was significantly longer in AVONEX-treated patients than in placebo-treated patients in Study 1 (p = 0.02). The percentage of patients progressing by the end of 2 years was 35% for placebo-treated patients and 22% for AVONEX-treated patients. This represents a 37% relative reduction in the risk of accumulating <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> in the AVONEX-treated group compared to the placebo-treated group.<br><br></p>
<p class="MultiMediaCaption"><a name="fig1"></a><span class="Bold">Figure 1: Time to Onset of Sustained <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Progression in Patients with MS in Study 1</span><span class="Sup">1</span></p>
<div class="Figure">
<a name="f01"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-01.jpg">
</div>
<p>1 Kaplan-Meier Methodology; <span class="Italics"><span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> progression was defined as at least a 1 point increase in EDSS score sustained for at least 6 months.</span></p>
<p>The distribution of confirmed EDSS change from study entry (baseline) to the end of the study is shown in <a href="#fig2">Figure 2</a>. There was a statistically significant difference between the AVONEX and placebo groups in confirmed change for patients with at least 2 scheduled visits (p = 0.006).<br><br></p>
<p class="MultiMediaCaption"><a name="fig2"></a><span class="Bold">Figure 2: Confirmed Change in EDSS from Study Entry to End of Study 1</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-11.2"></a><p></p>
<p class="First"><span class="Italics Underline">Exacerbations</span></p>
<p>The rate and frequency of MS exacerbations were secondary outcomes. For all patients included in the study, irrespective of time on study, the annual exacerbation rate was 0.67 per year in the AVONEX-treated group and 0.82 per year in the placebo-treated group (p = 0.04).
</p>
<p>AVONEX treatment significantly decreased the frequency of exacerbations in the subset of patients who were enrolled in the study for at least 2 years (87 placebo-treated patients and 85 AVONEX-treated patients; p = 0.03; see <a href="#t3">Table 3</a>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-11.3"></a><p></p>
<p class="First"><span class="Italics Underline">MRI Results</span></p>
<p>Gadolinium (Gd)-enhanced and T2-weighted magnetic resonance imaging (MRI) scans of the brain were obtained in most patients at baseline and at the end of 1 and 2 years of treatment. Secondary outcomes included Gd-enhanced lesion number and volume, and T2-weighted lesion volume. Gd-enhancing lesions seen on brain MRI scans represent areas of breakdown of the blood brain barrier thought to be secondary to <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. AVONEX-treated patients demonstrated significantly lower Gd-enhanced lesion number after 1 and 2 years of treatment than placebo-treated patients (p â‰¤ 0.05; see <a href="#t3">Table 3</a>). The volume of Gd-enhanced lesions showed similar treatment effects in the AVONEX and placebo groups (p â‰¤ 0.03). Percentage change in T2-weighted lesion volume from study entry to Year 1 was significantly lower in AVONEX-treated than placebo-treated patients (p = 0.02). A significant difference in T2-weighted lesion volume change was not seen between study entry and Year 2 in the AVONEX and placebo groups.
</p>
<p>The exact relationship between MRI findings and the clinical status of MS patients is unknown. The prognostic significance of MRI findings in these studies has not been evaluated.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-11.4"></a><p></p>
<p class="First"><span class="Italics">Summary of Effects of Clinical and MRI Endpoints in Study 1</span></p>
<p>A summary of the effects of AVONEX on the clinical and MRI endpoints of this study is presented in <a href="#t3">Table 3</a>.
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3: Clinical and MRI Endpoints in Patients with MS in Study 1
</span></caption>
<col align="left" width="45.289%">
<col align="left" width="23.494%">
<col align="left" width="15.046%">
<col align="left" width="16.171%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote">Â 
</p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Italics">Note: (N: , ) denotes the number of evaluable placebo and AVONEX patients, respectively.</span></p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Italics"><span class="Sup">1</span>Patient data included in this analysis represent variable periods of time on study.</span></p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Italics"><span class="Sup">2</span>Analyzed by Mantel-Cox (logrank) test.</span></p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Italics"><span class="Sup">3</span>Analyzed by Mann-Whitney rank-sum test.</span></p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Italics"><span class="Sup">4</span>Analyzed by Cochran-Mantel-Haenszel test.</span></p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Italics"><span class="Sup">5</span>Analyzed by likelihood ratio test.</span></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top">Â  Â  Â 
</td>
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Endpoint
</td>
<td align="left" valign="top">Placebo
</td>
<td align="left" valign="top">AVONEX
</td>
<td align="left" valign="top">P-Value
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Â  Â  Â 
</td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Underline">PRIMARY ENDPOINT</span>:
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Time to sustained progression
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">in <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> (N: 143, 158)<span class="Sup">1</span>
</td>
<td align="left" valign="top">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â ---See <a href="#fig1">Figure 1</a>---
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top">0.02<span class="Sup">2</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Percentage of patients progressing
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">in <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> at 2 years
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">(Kaplan-Meier estimate)<span class="Sup">1</span>
</td>
<td align="left" valign="top">35%
</td>
<td align="left" valign="top">22%
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Underline">SECONDARY ENDPOINTS</span>:
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">DISABILITY</span></span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Mean confirmed change in EDSS
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">from study entry to end of study
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">(N: 136, 150)<span class="Sup">1</span>
</td>
<td align="left" valign="top">0.50
</td>
<td align="left" valign="top">0.20
</td>
<td align="left" valign="top">0.006<span class="Sup">3</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">EXACERBATIONS</span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Number of exacerbations in subset
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">completing 2 years (N: 87, 85)
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 0
</td>
<td align="left" valign="top">26%
</td>
<td align="left" valign="top">38%
</td>
<td align="left" valign="top">0.03<span class="Sup">3</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 1
</td>
<td align="left" valign="top">30%
</td>
<td align="left" valign="top">31%
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 2
</td>
<td align="left" valign="top">11%
</td>
<td align="left" valign="top">18%
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 3
</td>
<td align="left" valign="top">14%
</td>
<td align="left" valign="top">7%
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â â‰¥4
</td>
<td align="left" valign="top">18%
</td>
<td align="left" valign="top">7%
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Percentage of patients exacerbation-
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">free in subset completing 2 years
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">(N: 87, 85)
</td>
<td align="left" valign="top">26%
</td>
<td align="left" valign="top">38%
</td>
<td align="left" valign="top">0.10<span class="Sup">4</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Annual exacerbation rate
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">(N: 143, 158)<span class="Sup">1</span>
</td>
<td align="left" valign="top">0.82
</td>
<td align="left" valign="top">0.67
</td>
<td align="left" valign="top">0.04<span class="Sup">5</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">MRI</span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Underline">Number of Gd-enhanced lesions</span>:
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">At study entry (N: 132, 141)
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â Mean (Median)
</td>
<td align="left" valign="top">2.3 (1.0)
</td>
<td align="left" valign="top">3.2 (1.0)
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â Range
</td>
<td align="left" valign="top">0-23
</td>
<td align="left" valign="top">0-56
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Year 1 (N: 123, 134)
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â Mean (Median)
</td>
<td align="left" valign="top">1.6 (0)
</td>
<td align="left" valign="top">1.0 (0)
</td>
<td align="left" valign="top">0.02<span class="Sup">3</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â Range
</td>
<td align="left" valign="top">0-22
</td>
<td align="left" valign="top">0-28
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Year 2 (N: 82, 83)
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â Mean (Median)
</td>
<td align="left" valign="top">1.6 (0)
</td>
<td align="left" valign="top">0.8 (0)
</td>
<td align="left" valign="top">0.05<span class="Sup">3</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â Range
</td>
<td align="left" valign="top">0-34
</td>
<td align="left" valign="top">0-13
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Underline">T2 lesion volume</span>:
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Percentage change from study
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">entry to Year 1 (N: 116, 123)
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â Median
</td>
<td align="left" valign="top">-3.3%
</td>
<td align="left" valign="top">-13.1%
</td>
<td align="left" valign="top">0.02<span class="Sup">3</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Percentage change from study
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">entry to Year 2 (N: 83, 81)
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr class="Last">
<td align="left" valign="top">Â  Â  Â Median
</td>
<td align="left" valign="top">-6.5%
</td>
<td align="left" valign="top">-13.2%
</td>
<td align="left" valign="top">0.36<span class="Sup">3</span>
</td>
</tr>
</tbody>
</table>
<p>In Study 2, 383 patients who had recently experienced an isolated demyelinating event involving the optic nerve, spinal cord, or brainstem/cerebellum, and who had lesions typical of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> on brain MRI, received either 30 micrograms of AVONEX (n = 193) or placebo (n = 190) by intramuscular injection once weekly. Patients were enrolled into the study over a two-year period and followed for up to three years or until they developed a second clinical exacerbation in an anatomically distinct region of the central nervous system.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-11.5"></a><p></p>
<p class="First"><span class="Italics Underline">Exacerbations</span></p>
<p>In Study 2, the primary outcome measure was time to development of a second exacerbation in an anatomically distinct region of the central nervous system. Time to development of a second exacerbation was significantly delayed in AVONEX-treated compared to placebo-treated patients (p = 0.002). The Kaplan-Meier estimates of the percentage of patients developing an exacerbation within 24 months were 39% in the placebo group and 21% in the AVONEX group (see <a href="#fig3">Figure 3</a>). The relative rate of developing a second exacerbation in the AVONEX group was 0.56 of the rate in the placebo group (95% confidence interval 0.38 to 0.81).<br><br></p>
<p class="MultiMediaCaption"><a name="fig3"></a><span class="Bold">Figure 3: Time to onset of a Second Exacerbation in Study 2</span><span class="Sup">1</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Figure 3
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-03.jpg">
</div>
<p>1 Kaplan-Meier Methodology
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-11.6"></a><p></p>
<p class="First"><span class="Italics Underline">MRI Findings</span></p>
<p>Secondary outcomes were brain MRI measures, including the cumulative increase in the number of new or enlarging T2 lesions, T2 lesion volume at baseline compared to results at 18 months, and the number of Gd-enhancing lesions at 6 months. See <a href="#t4">Table 4</a> for the MRI results.
</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4: Brain MRI Results in Study 2
</span></caption>
<col align="left" width="40.000%">
<col align="left" width="25.000%">
<col align="left" width="35.000%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">1</span> P value &lt;0.001
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">2</span> P value &lt;0.03
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">* P value from a Mann-Whitney rank-sum test
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"></td>
<td class="Botrule Toprule" align="center" valign="top">AVONEX
</td>
<td class="Botrule Toprule" align="center" valign="top">Placebo
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">CHANGE FROM BASELINE IN T2</span></td>
<td align="center" valign="top">N = 119
</td>
<td align="center" valign="top">N = 109
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">VOLUME OF LESIONS AT 18</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">MONTHS:</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">Â  Â  Â 
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">Actual Change (mm<span class="Sup">3</span>)<span class="Sup">1*</span>
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">Median (25<span class="Sup">th</span>%, 75<span class="Sup">th</span>%)
</td>
<td align="center" valign="top">28 (-576, 397)
</td>
<td align="center" valign="top">313 (5, 1140)
</td>
</tr>
<tr>
<td align="center" valign="top">Â  Â  Â 
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">Percentage Change<span class="Sup">1*</span>
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">Median (25<span class="Sup">th</span>%, 75<span class="Sup">th</span>%)
</td>
<td align="center" valign="top">1 (-24, 29)
</td>
<td align="center" valign="top">16 (0, 53)
</td>
</tr>
<tr>
<td align="center" valign="top">Â  Â  Â 
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">NUMBER OF NEW OR ENLARGING</span></td>
<td align="center" valign="top">N = 132
</td>
<td align="center" valign="top">N = 119
</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Underline">T2 LESIONS AT 18 MONTHS</span><span class="Sup">1*</span>:
</td>
<td align="center" valign="top">N (%)
</td>
<td align="center" valign="top">N (%)
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">62 (47)
</td>
<td align="center" valign="top">22 (18)
</td>
</tr>
<tr>
<td align="center" valign="top">1-3
</td>
<td align="center" valign="top">41 (31)
</td>
<td align="center" valign="top">47 (40)
</td>
</tr>
<tr>
<td align="center" valign="top">â‰¥4
</td>
<td align="center" valign="top">29 (22)
</td>
<td align="center" valign="top">50 (42)
</td>
</tr>
<tr>
<td align="center" valign="top">Mean (SD)
</td>
<td align="center" valign="top">2.13 (3.2)
</td>
<td align="center" valign="top">4.97 (7.7)
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">NUMBER OF GD-ENHANCING</span></td>
<td align="center" valign="top">N = 165
</td>
<td align="center" valign="top">N = 152
</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Underline">LESIONS AT 6 MONTHS</span><span class="Sup">2*</span>:
</td>
<td align="center" valign="top">N (%)
</td>
<td align="center" valign="top">N (%)
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â 
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">115 (70)
</td>
<td align="center" valign="top">93 (61)
</td>
</tr>
<tr>
<td align="center" valign="top">1
</td>
<td align="center" valign="top">27 (16)
</td>
<td align="center" valign="top">16 (11)
</td>
</tr>
<tr>
<td align="center" valign="top">&gt;1
</td>
<td align="center" valign="top">23 (14)
</td>
<td align="center" valign="top">43 (28)
</td>
</tr>
<tr>
<td align="center" valign="top">Mean (SD)
</td>
<td align="center" valign="top">0.87 (2.3)
</td>
<td align="center" valign="top">1.49 (3.1)
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Â  Â  Â 
</td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s47"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-12.1"></a><p></p>
<h2>16.1 AVONEX Lyophilized Powder Vial
</h2>
<p class="First">A vial of AVONEX is supplied as a lyophilized powder in a single-use vial containing 33 micrograms (6.6 million international units) of interferon beta-1a; 16.5 mg Albumin (Human), USP; 6.4 mg Sodium Chloride, USP; 6.3 mg Dibasic Sodium Phosphate, USP; and 1.3 mg Monobasic Sodium Phosphate, USP, and is preservative-free. Diluent is supplied in a single-use vial (Sterile Water for Injection, USP).
</p>
<p>AVONEX lyophilized vials are available in the following package configuration (NDC 59627-001-03): A package containing four Administration Dose Packs (each containing one vial of AVONEX, one 10 mL diluent vial, two alcohol wipes, one gauze pad, one 3 mL syringe, one MICRO PIN<span class="Sup">Â®</span>* vial access pin, one 23 gauge, 1Â¼ inch needle, and one adhesive bandage).
</p>
<p>Vials of AVONEX should be stored in a 2Â°C to 8Â°C (36Â°F to 46Â°F) refrigerator. Should refrigeration be unavailable, vials of AVONEX can be stored at 25Â°C (77Â°F) for a period of up to 30 days. DO NOT EXPOSE TO <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">HIGH TEMPERATURES</span>. DO NOT FREEZE. Protect from light. Do not use beyond the expiration date stamped on the vial. Following reconstitution, it is recommended the product be used as soon as possible within 6 hours stored at 2Â°C to 8Â°C (36Â°F to 46Â°F). DO NOT FREEZE RECONSTITUTED AVONEX.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-12.2"></a><p></p>
<h2>16.2 AVONEX Single-Use Prefilled Syringe
</h2>
<p class="First">A prefilled syringe of AVONEX is supplied as a sterile liquid albumin-free formulation containing 30 micrograms of interferon beta-1a, 0.79 mg Sodium Acetate Trihydrate, USP; 0.25 mg Glacial Acetic Acid, USP; 15.8 mg Arginine Hydrochloride, USP; and 0.025 mg Polysorbate 20 in Water for Injection, USP. Each prefilled glass syringe contains 0.5 mL for Intramuscular injection.
</p>
<p>AVONEX prefilled syringes are available in the following package configuration (NDC 59627-002-05): A package containing four Administration Dose Packs (each containing one single-use syringe of AVONEX and one 23 gauge, 1Â¼ inch needle), and a recloseable accessory pouch containing 4 alcohol wipes, 4 gauze pads, and 4 adhesive bandages.
</p>
<p>AVONEX in prefilled syringes should be stored in a 2Â°C to 8Â°C (36Â°F to 46Â°F) refrigerator. Once removed from the refrigerator, AVONEX in a prefilled syringe should be allowed to warm to room temperature (about 30 minutes). Do not use external heat sources such as hot water to warm AVONEX in a prefilled syringe. Should refrigeration be unavailable, AVONEX in a prefilled syringe can be stored at â‰¤ 25Â°C (77Â°F) for a period up to 7 days. Once the product is removed from the refrigerator, it must not be stored above 25Â°C (77Â°F). If the product has been exposed to conditions other than those recommended, <span class="Bold">DISCARD THE PRODUCT and DO NOT USE</span>. DO NOT EXPOSE TO <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">HIGH TEMPERATURES</span>. DO NOT FREEZE. Protect from light. Do not use beyond the expiration date stamped on the syringe.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-12.3"></a><p></p>
<h2>16.3 AVONEX PEN Single-Use Prefilled Autoinjector
</h2>
<p class="First">AVONEX PEN is supplied as a sterile liquid albumin-free formulation containing 30 micrograms of interferon beta-1a, 0.79 mg Sodium Acetate Trihydrate, USP; 0.25 mg Glacial Acetic Acid, USP; 15.8 mg Arginine Hydrochloride, USP; and 0.025 mg Polysorbate 20 in Water for Injection, USP. Each single-use prefilled autoinjector contains 0.5 mL for intramuscular injection.
</p>
<p>AVONEX PEN single-use prefilled autoinjectors are available in the following package configuration (NDC 59627-003-04): A package containing four AVONEX PEN Administration Dose Packs (each containing one AVONEX PEN autoinjector, one 25 gauge, 5/8 inch needle and an AVONEX PEN cover), and a recloseable accessory pouch containing 4 alcohol wipes, 4 gauze pads, and 4 adhesive bandages.
</p>
<p>AVONEX PEN should be stored in a 2Â°C to 8Â°C (36Â°F to 46Â°F) refrigerator. Once removed from the refrigerator, AVONEX PEN should be allowed to warm to room temperature (about 30 minutes). Do not use external heat sources such as hot water to warm AVONEX. Should refrigeration be unavailable, AVONEX PEN can be stored at â‰¤ 25Â°C (77Â°F) for a period up to 7 days. Once the product is removed from the refrigerator, it must not be stored above 25Â°C (77Â°F). If the product has been exposed to conditions other than those recommended, <span class="Bold">DISCARD THE PRODUCT and DO NOT USE</span>. DO NOT EXPOSE TO <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">HIGH TEMPERATURES</span>. DO NOT FREEZE. Protect from light. Do not use beyond the expiration date stamped on the prefilled autoinjector.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s51"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">See FDA-approved patient labeling (Medication Guide and Patient's Instructions for Use).
</p>
<p>Instruct patients to carefully read the supplied AVONEX Medication Guide and caution patients not to change the AVONEX dose or schedule of administration without medical consultation.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-13.1"></a><p></p>
<h2>17.1 Instruction on Self-injection Technique and Procedures
</h2>
<p class="First">Provide appropriate instruction for reconstitution of AVONEX and methods of self-injection, including careful review of the AVONEX Medication Guide. Instruct patients in the use of aseptic technique when administering AVONEX.
</p>
<p>Inform patients that their healthcare provider should show them or their caregiver how to prepare and inject AVONEX before administering the first dose. Their healthcare provider should watch the first AVONEX injection given. Tell patients not to re-use needles or syringes and instruct patients on safe disposal procedures. Inform patients to dispose of used needles and syringes in a puncture-resistant container and instruct the patient regarding safe disposal of full containers.
</p>
<p>Advise patients:
</p>
<ul class="Disc">
<li>of the importance of rotating areas of injection with each dose to minimize the likelihood of <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>. [see <span class="Italics">Choose an Injection Site section of the Medication Guide]</span>.
</li>
<li>NOT to inject area of the body where the skin is irritated, reddened, bruised, infected or scarred in any way
</li>
<li>to check the injection site after 2 hours for <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>
</li>
<li>contact their doctor or nurse if they have a <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> and it does not clear up in a few days
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-13.2"></a><p></p>
<h2>17.2 Pregnancy
</h2>
<p class="First">Advise patients that AVONEX should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus [see <span class="Italics">Use in Special Population (<a href="#s22">8.1</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-13.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>
</h2>
<p class="First">Advise patients of the symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic disorders</span> as they have been reported with the use of AVONEX and instruct patients to report them immediately to their physician [see <span class="Italics">Warnings and Precautions (<a href="#s9">5.1</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-13.4"></a><p></p>
<h2>17.4 Liver Disease
</h2>
<p class="First">Advise patients that severe hepatic injury, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, has been reported during the use of AVONEX. Advise patients of symptoms of hepatic dysfunction, and instruct patients to report them immediately to their physician [see <span class="Italics">Warnings and Precautions (<a href="#s10">5.2</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-13.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>
</h2>
<p class="First">Advise patients of the symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and instruct patients to seek immediate medical attention if these symptoms occur [see <span class="Italics">Warnings and Precautions (<a href="#s11">5.3</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-13.6"></a><p></p>
<h2>17.6 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>
</h2>
<p class="First">Advise patients that worsening of pre-existing <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> has been reported in patients using AVONEX. Advise patients of symptoms of worsening cardiac condition, and instruct patients to report them immediately to their physician [see <span class="Italics">Warnings and Precautions (<a href="#s12">5.4</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-13.7"></a><p></p>
<h2>17.7 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</h2>
<p class="First">Advise patients that <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have been reported in patients using AVONEX. Instruct patients to report <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> immediately to their physician [see <span class="Italics">Warnings and Precautions (<a href="#s14">5.6</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-13.8"></a><p></p>
<h2>17.8 Flu-like Symptoms
</h2>
<p class="First">Inform patients that flu-like symptoms are common following initiation of therapy with AVONEX [see <span class="Italics">Dosage and Administration (<a href="#s5">2.3</a>) and Adverse Reactions (<a href="#s17">6</a>)</span>]. Advise patients that starting with a lower dose than 30 micrograms and increasing the dose over 3 weeks reduces the incidence and severity of flu-like symptoms.
</p>
<p>Manufactured by: <br>BIOGEN IDEC INC. <br>14 Cambridge Center <br>Cambridge, MA 02142 USA <br>Â©1996-2012 Biogen Idec Inc. All rights reserved. <br>1-800-456-2255
</p>
<p><span class="Italics">*Micro Pin</span><span class="Sup">Â®
</span><span class="Italics">is the trademark of B. Braun Medical Inc.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s60"></a><a name="section-14"></a><p></p>
<p class="First"><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">AVONEX</span><span class="Sup">Â®
</span><span class="Bold">(a-vuh-necks)</span></p>
<p><span class="Bold">(interferon beta-1a)</span></p>
<p><span class="Bold">Injection for intramuscular use</span></p>
<p>Read this Medication Guide before you start using AVONEX, and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.
</p>
<p><a name="p01"></a><span class="Bold">What is the most important information I should know about AVONEX?</span></p>
<p><span class="Bold">AVONEX can cause serious side effects.</span> Tell your healthcare provider right away if you have any of the symptoms listed below while taking AVONEX.
</p>
<ol class="Arabic">
<li>
<span class="Bold"> Behavioral health problems including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>.</span> Some people taking AVONEX may develop mood or behavior problems including:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> (getting upset easily)
</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (feeling hopeless or feeling bad about yourself)
</li>
<li><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>
</li>
<li>thoughts of hurting yourself or <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>
</li>
<li>hearing or seeing things that others do not hear or see (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>)
</li>
</ul>
</li>
<li>
<span class="Bold"> Liver problems, or worsening of liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Symptoms may include:</span><table width="100%">
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tbody class="Headless"><tr class="First Last">
<td align="left" valign="top"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>
</li>
<li>loss of appetite
</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>
</li>
<li>dark colored urine and <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> stools
</li>
</ul></td>
<td align="left" valign="top"><ul class="Disc">
<li>yellowing of your skin or the white part of your eye
</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> more easily than normal
</li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>
</li>
</ul></td>
</tr></tbody>
</table>
<p class="First">During your treatment with AVONEX you will need to see your healthcare provider regularly and have regular blood tests to check for side effects.
</p>
</li>
<li>
<span class="Bold"> Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. Symptoms may include:</span><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, eyes, lips, tongue or throat
</li>
<li>trouble breathing
</li>
<li>anxiousness
</li>
<li>feeling <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, sores in your mouth, or your skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> and peels
</li>
</ul>
</li>
</ol>
<p><span class="Bold">What is AVONEX?</span></p>
<p>AVONEX is a form of a protein called beta interferon that occurs naturally in the body. AVONEX is a prescription medicine used to treat adults with relapsing forms of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> (MS). This includes people who have had their first symptoms of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> and have an MRI consistent with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>.
</p>
<p>AVONEX will not cure your MS but may decrease the number of flare-ups of the disease and slow the occurrence of some of the physical <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> that is common in people with MS. MS is a life-long disease that affects your nervous system by destroying the protective covering (myelin) that surrounds your nerve fibers.
</p>
<p>The way AVONEX works in MS is not known.
</p>
<p>It is not known if AVONEX is safe and effective in children.
</p>
<p><span class="Bold">Who should not use AVONEX?</span></p>
<p><span class="Bold">Do not take AVONEX if you:</span></p>
<ul class="Disc"><li>are allergic to interferon beta, albumin (human), or any of the ingredients in AVONEX. See the end of this Medication Guide for a complete list of ingredients in AVONEX.
</li></ul>
<p><span class="Bold">What should I tell my healthcare provider before using AVONEX?</span></p>
<p><span class="Bold">Before taking AVONEX, tell your healthcare provider if you:</span></p>
<ul class="Disc">
<li>are being treated for a mental illness or had treatment in the past for any mental illness, including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>
</li>
<li>have or had <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems or blood clots
</li>
<li>have or had low blood cell counts
</li>
<li>have or had liver problems
</li>
<li>have or had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>)
</li>
<li>have or had heart problems
</li>
<li>have or had thyroid problems
</li>
<li>have or had any kind of autoimmune disease (where the body's immune system attacks the body's own cells), such as <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, or <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>
</li>
<li>drink alcohol
</li>
<li>are pregnant or plan to become pregnant. It is not known if AVONEX will harm your unborn baby. Tell your healthcare provider if you become pregnant during your treatment with AVONEX.
</li>
<li>are breastfeeding or plan to breastfeed. It is not known if AVONEX passes into your breast milk. You and your healthcare provider should decide if you will use AVONEX or breastfeed. You should not do both.
</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements.
</p>
<p><span class="Bold">How should I use AVONEX?</span></p>
<ul class="Disc">
<li>Your healthcare provider should show you how to prepare and measure your dose of AVONEX and how to inject your AVONEX before you use AVONEX for the first time.
</li>
<li>Your healthcare provider or nurse should watch the first AVONEX injection you give yourself.
</li>
<li>AVONEX is given once a week by injection into the muscle (intramuscular injection).
</li>
<li>Inject AVONEX exactly as your healthcare provider tells you.
</li>
<li>Your healthcare provider will tell you how much AVONEX to inject and how often to inject AVONEX. <span class="Bold">Do not</span> inject more than your healthcare provider tells you to.
</li>
<li>
<span class="Bold">Do not</span> change your dose unless your healthcare provider tells you to.
</li>
<li>Change (rotate) your injection site you choose with each injection. This will help decrease the chance that you will have an <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>.
</li>
<li>
<span class="Bold">Do not</span> inject into an area of the body where the skin is irritated, reddened, bruised, infected or scarred in any way.
</li>
<li>AVONEX comes as a:<ul class="Circle">
<li>Vial with freeze-dried (lyophilized) powder
</li>
<li>Prefilled syringe (can be used with the AVOSTARTGRIPâ„¢ titration kit)
</li>
<li>Single-Use Prefilled Autoinjector Pen (AVONEX<span class="Sup">Â®</span> PENâ„¢)
</li>
</ul>
</li>
</ul>
<p>Your healthcare provider will decide which one is best for you. See the Instructions for Use at the end of this Medication Guide for detailed instructions for preparing and injecting your dose of AVONEX.
</p>
<ul class="Disc"><li>Always use a new, unopened AVONEX vial, prefilled syringe, or single-use prefilled autoinjector pen for each intramuscular injection.
</li></ul>
<p><span class="Bold">What are the possible side effects of AVONEX?</span></p>
<p><span class="Bold">AVONEX can cause serious side effects including:</span></p>
<ul class="Disc">
<li><span class="Bold">See â€œ<a href="#p01">What is the most important information I should know about AVONEX?</a>â€?</span></li>
<li>
<span class="Bold">Heart problems, including <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span> While AVONEX is not known to have any direct effects on the heart, a few patients who did not have a history of heart problems developed heart muscle problems or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> after taking AVONEX. If you already have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, AVONEX may cause your <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> to get worse. Call your healthcare provider right away if you have worsening symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your lower legs or feet while using AVONEX.<ul class="Circle"><li>Some people using AVONEX may have other heart problems including:<ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>
</li>
<li>fast or abnormal heart beat
</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or a heart muscle problem (<span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>)
</li>
</ul>
</li></ul>
</li>
<li>
<span class="Bold">Blood problems.</span> AVONEX can affect your bone marrow and cause low red and white blood cell, and platelet counts. In some people, these blood cell counts may <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> to dangerously low levels. If your blood cell counts become very low, you can get <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and problems with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>.
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>.</span> Some patients have had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> while taking AVONEX, including patients who have never had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> before.
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>.</span> Some people who take AVONEX may get an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may include:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or burning with urination
</li>
<li>urinating often
</li>
<li><span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up mucus
</li>
</ul>
</li>
<li>
<span class="Bold">Thyroid problems.</span> Some people taking AVONEX develop changes in their thyroid function. Symptoms of thyroid changes include:<ul class="Circle">
<li>problems concentrating
</li>
<li><span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">feeling cold</span> or hot all the time
</li>
<li>weight changes (gain or loss)
</li>
<li>skin changes
</li>
</ul>
</li>
</ul>
<p><span class="Bold">Tell your healthcare provider right away if you have any of the symptoms listed above.</span></p>
<p>The most common side effects of AVONEX include:
</p>
<ul class="Disc"><li>Flu-like symptoms. Most people who take AVONEX have flu-like symptoms early during the course of therapy. Usually, these symptoms last for a day after the injection. You may be able to manage these flu-like symptoms by taking over-the-counter <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> reducers. For many people, these symptoms lessen or go away over time. Symptoms may include:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>
</li>
</ul>
</li></ul>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</p>
<p><span class="Bold">How should I store AVONEX?</span></p>
<ul class="Disc">
<li>Store AVONEX in the refrigerator at 36Â°F to 46Â°F (2Â°C to 8Â°C).
</li>
<li>
<span class="Bold">Do not</span> freeze AVONEX. <span class="Bold">Do not</span> use AVONEX that has been frozen.
</li>
<li>
<span class="Bold">Do not</span> store AVONEX above 77Â°F (25Â°C).
</li>
<li>Keep AVONEX away from light.
</li>
<li>
<span class="Bold">Do not</span> use AVONEX past the expiration date.
</li>
<li>If you cannot refrigerate your AVONEX vials, you can store your AVONEX vials at 77Â°F (25Â°C) for up to 30 days. After mixing, the AVONEX solution should be used immediately, within 6 hours when stored refrigerated at 36Â°F to 46Â°F (2Â°C to 8Â°C).
</li>
<li>If you cannot refrigerate your AVONEX PEN and AVONEX prefilled syringes, you can store your AVONEX PEN and AVONEX prefilled syringes up to 77Â°F (25Â°C) for up to 7 days.
</li>
</ul>
<p><span class="Bold">Keep AVONEX vials, prefilled syringes, pens and all other medicines out of the reach of children.</span></p>
<p><span class="Bold">General advice about the safe and effective use of AVONEX</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. <span class="Bold">Do not</span> use AVONEX for a condition for which it was not prescribed. <span class="Bold">Do not</span> give AVONEX to other people, even if they have the same symptoms that you have, it may harm them.
</p>
<p>This Medication Guide summarizes the most important information about AVONEX. If you would like more information, talk with your healthcare provider. You may ask your healthcare provider or pharmacist for information about AVONEX that is written for healthcare professionals.
</p>
<p><span class="Bold">What are the ingredients in AVONEX?</span></p>
<p><span class="Bold">Active ingredient:</span> interferon beta-1a
</p>
<p><span class="Bold">Inactive ingredients:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Vial with freeze-dried (lyophilized) powder:</span> albumin (human), sodium chloride, dibasic sodium phosphate, and monobasic sodium phosphate.
</li>
<li>
<span class="Bold">Single-Use Prefilled Syringe:</span> sodium acetate trihydrate, glacial acetic acid, arginine hydrochloride, polysorbate 20 in water for injection.
</li>
<li>
<span class="Bold">Single-Use Prefilled Autoinjector Pen:</span> sodium acetate trihydrate, glacial acetic acid, arginine hydrochloride, polysorbate 20 in water for injection.
</li>
</ul>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.
</p>
<p>Manufactured by:<br>BIOGEN IDEC INC.<br>14 Cambridge Center<br>Cambridge, MA 02142 USA<br>Â©1996-2012 Biogen Idec Inc. All rights reserved.<br>1-800-456-2255
</p>
<p>Revised 02/2012
</p>
<p><span class="Bold">Medication Guide Appendix: Instructions for Preparing and Giving a Dose with an AVONEX</span><span class="Sup">Â®
</span><span class="Bold Underline">Vial</span></p>
<p><span class="Bold">Storing AVONEX</span><span class="Sup">Â®
</span><span class="Bold">Vials</span></p>
<p>Prior to use, AVONEX<span class="Sup">Â®</span> should be refrigerated (36-46Â°F or 2-8Â°C) but can be kept for up to 30 days at room temperature (77Â°F or 25Â°C). You should avoid exposing AVONEX<span class="Sup">Â®</span> to <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">high temperatures</span> and freezing. After mixing, AVONEX<span class="Sup">Â®</span> solution should be used immediately, within 6 hours when stored refrigerated at 36-46Â°F or 2-8Â°C. Do not freeze the AVONEX<span class="Sup">Â®</span> solution.
</p>
<p><span class="Bold">How do I prepare and inject a dose of AVONEX</span><span class="Sup">Â®</span><span class="Bold">?</span></p>
<p>Find a well-lit, clean, flat work surface like a table and collect all the supplies you will need to give yourself or receive an injection. You may want to take one AVONEX<span class="Sup">Â®</span> Administration Dose Pack out of the refrigerator about 30 minutes before you plan on injecting your dose to allow it to reach room temperature. A room temperature solution is more comfortable to inject.
</p>
<p>You will need the following supplies:
</p>
<ul class="Disc">
<li>vial of AVONEX<span class="Sup">Â®</span> (white to off-white powder or cake)
</li>
<li>vial of diluent, single-use (Sterile Water for Injection, USP)
</li>
<li>3 mL syringe
</li>
<li>blue MICRO PIN<span class="Sup">Â®</span> (vial access pin)
</li>
<li>sterile needle
</li>
<li>alcohol wipes
</li>
<li>gauze pad
</li>
<li>adhesive bandage
</li>
<li>a puncture resistant container for disposal of used syringes, needles, and MICRO PINS.
</li>
</ul>
<p><span class="Bold">Preparing the AVONEX</span><span class="Sup">Â®
</span><span class="Bold">solution</span></p>
<p>It is important to keep your work area, your hands, and your injection site clean to minimize risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. You should wash your hands prior to preparing the medication.
</p>
<ol class="Arabic">
<li>Check the expiration date on the AVONEX<span class="Sup">Â®</span> vial and the vial of diluent; do not use if the medication or diluent is expired.
</li>
<li>Remove the caps from the vial of AVONEX<span class="Sup">Â®</span> and the vial of diluent, and clean the rubber stopper on the top of each vial with an alcohol wipe.<p class="First"><a name="f04"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-04.jpg"></p>
</li>
<li>Attach the blue MICRO PIN<span class="Sup">Â®</span> to the syringe by turning clockwise until secure. <span class="Italics">NOTE: Over-tightening can make the MICRO PIN<span class="Sup">Â®</span> difficult to remove.</span><p class="First"><a name="f05"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-05.jpg"></p>
</li>
<li>Pull the MICRO PIN<span class="Sup">Â®</span> cover straight off; do not twist. Save the cover for later use.<p class="First"><a name="f06"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-06.jpg"></p>
</li>
<li>Pull back the syringe plunger to the 1.1 mL mark.<p class="First"><a name="f07"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-07.jpg"></p>
</li>
<li>Firmly push the MICRO PIN<span class="Sup">Â®</span> down through the <span class="Bold">center</span> of the rubber stopper of the diluent vial.<p class="First"><a name="f08"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-08.jpg"></p>
</li>
<li>Inject the air in the syringe into the diluent vial by pushing down on the plunger until it cannot be pushed any further.
</li>
<li>Keeping the MICRO PIN<span class="Sup">Â®</span> in the vial, turn the diluent vial and syringe upside down.
</li>
<li>While keeping the MICRO PIN<span class="Sup">Â®</span> in the fluid, slowly pull back on the plunger to withdraw 1.1 mL of diluent into the syringe.<p class="First"><a name="f09"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-09.jpg"></p>
</li>
<li>Gently tap the syringe with your finger to make any air bubbles rise to the top. If bubbles are present, slowly press the plunger in (to push just the bubbles out through the needle). Make sure there is still 1.1 mL of diluent in the syringe.<p class="First"><a name="f10"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-10.jpg"></p>
</li>
<li>Slowly pull the MICRO PIN<span class="Sup">Â®</span> out of the diluent vial.
</li>
<li>Carefully insert the MICRO PIN<span class="Sup">Â®</span> through the <span class="Bold">center</span> of the rubber stopper of the vial of AVONEX<span class="Sup">Â®</span>. <span class="Italics">NOTE: Off-center punctures can push the stopper into the vial. If the stopper <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> into the vial, do not use.</span>
</li>
<li>
<span class="Bold"> Slowly</span> inject the diluent into the vial of AVONEX<span class="Sup">Â®</span>. DO NOT aim the stream of diluent directly on the AVONEX<span class="Sup">Â®</span> powder. Too direct or forceful a stream of diluent onto the powder may cause foaming, and make it difficult to withdraw AVONEX<span class="Sup">Â®</span>.<p class="First"><a name="f11"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-11.jpg"></p>
</li>
<li>Without removing the syringe, <span class="Bold">gently</span> swirl the vial until the AVONEX<span class="Sup">Â®</span> is dissolved. <span class="Bold Italics">DO NOT SHAKE.</span><p class="First"><a name="f12"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-12.jpg"></p>
</li>
<li>Check to see that all of the AVONEX<span class="Sup">Â®</span> is dissolved. Check the solution in the vial of AVONEX<span class="Sup">Â®</span>. It should be clear to slightly yellow in color and should not have any particles. Do not use the vial if the solution is cloudy, has particles in it or is a color other than clear to slightly yellow.
</li>
<li>Turn the vial and syringe upside down. Slowly pull back on the plunger to withdraw 1.0 mL of AVONEX<span class="Sup">Â®</span>. If bubbles appear, push solution slowly back into the vial and withdraw the solution again.<p class="First"><a name="f13"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-13.jpg"></p>
</li>
<li>With the vial still upside down, tap the syringe <span class="Bold">gently</span> to make any air bubbles rise to the top. Then press the plunger in until the AVONEX<span class="Sup">Â®</span> is at the top of the syringe. Check the volume (should be 1.0 mL) and withdraw more medication if necessary. Withdraw the MICRO PIN<span class="Sup">Â®</span> and syringe from the vial.
</li>
<li>Replace the cover on the MICRO PIN<span class="Sup">Â®</span> and remove from the syringe with a counterclockwise turn.
</li>
<li>Attach the sterile needle for injection to the syringe turning clockwise until the needle is secure. A secure attachment will prevent leakage during the injection.<p class="First"><a name="f14"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-14.jpg"></p>
</li>
</ol>
<p><span class="Bold">Selecting an injection site</span></p>
<p>You should use a different site each time you inject. This can be as simple as switching between thighs (if you are always injecting yourself), or if another person is helping you, you can rotate between your upper arms and your thighs. Keeping a record of the date and location of each injection will help you.
</p>
<p>Do not inject into an area of the body where the skin is irritated, reddened, bruised, infected or scarred in any way. The best sites for intramuscular injection are the thigh and upper arm:
</p>
<ul class="Disc">
<li>thigh<p class="First"><a name="f15"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-15.jpg"></p>
</li>
<li>upper arm<p class="First"><a name="f16"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-16.jpg"></p>
</li>
</ul>
<p><span class="Bold">Injecting the AVONEX</span><span class="Sup">Â®
</span><span class="Bold">dose</span></p>
<ol class="Arabic">
<li>Use a new alcohol wipe to clean the skin at one of the recommended intramuscular injection sites. Then, pull the protective cover <span class="Bold">straight</span> off the needle; do not twist the cover off.
</li>
<li>With one hand, stretch the skin out around the injection site. Hold the syringe like a pencil with the other hand, and using a quick motion insert the needle at a 90Â° angle, through the skin and into the muscle.
</li>
<li>Once the needle is in, let go of the skin and use that hand to gently pull back slightly on the plunger. If you see blood come into the syringe, withdraw the needle from the injection site and put pressure on the site with a gauze pad. You will need to replace the needle and choose and clean a new site for injection.
</li>
<li>If no blood came into the syringe, slowly push the plunger in until the syringe is empty.<p class="First"><a name="f17"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-17.jpg"></p>
</li>
<li>Hold a gauze pad near the needle at the injection site and pull the needle straight out. Use the pad to apply pressure to the site for a few seconds or rub gently in a circular motion.<p class="First"><a name="f18"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-18.jpg"></p>
</li>
<li>If there is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> at the site, wipe it off and, if necessary, apply an adhesive bandage.
</li>
<li>Dispose of the used syringe, needle and blue MICRO PIN<span class="Sup">Â®</span> in your puncture resistant container. DO NOT USE a syringe, MICRO PIN<span class="Sup">Â®</span>, or needle more than once. The AVONEX<span class="Sup">Â®</span> and diluent vials should be put in the trash.
</li>
</ol>
<p><span class="Bold">Disposal of syringes and needles</span></p>
<p>There may be special state and/or local laws for disposing of used needles and syringes. Your doctor, nurse or pharmacist should provide you with instructions on how to dispose of your used needles and syringes.
</p>
<ul class="Disc">
<li><span class="Bold">Always keep your disposal container out of the reach of children.</span></li>
<li>DO NOT throw used needles and syringes into the household trash and DO NOT RECYCLE.
</li>
</ul>
<p>Manufactured by:<br>Biogen Idec Inc.<br>14 Cambridge Center<br>Cambridge, MA 02142 USA<br>Â©1996-2011 Biogen Idec Inc. All rights reserved.<br>1-800-456-2255
</p>
<p>Appendix Revision Date: 11/2004
</p>
<p>I63005-11
</p>
<p><span class="Italics">*Micro Pin</span><span class="Sup">Â®
</span><span class="Italics">is the trademark of B. Braun Medical Inc.</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s61"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ Lyophilized Powder 4 Pack Carton</span></p>
<p>NDC 59627-001-03
</p>
<p><span class="Bold">AVONEX<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(interferon beta-1a)</span></p>
<p>Rx only
</p>
<div class="Figure">
<a name="f19"></a><img alt="PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ Lyophilized Powder 4 Pack Carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-19.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s62"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ Lyophilized Powder Tray Lid</span></p>
<p>NDC  59627-001-04
</p>
<p><span class="Bold">AVONEX<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(interferon beta-1a)</span></p>
<p>Rx only
</p>
<p>Lyophilized Powder
</p>
<p>1 Tray (Administration Dose Pack) contains: 1 single-use vial containing 33 mcg interferon beta-1a, 1 single-use diluent vial, 1 syringe, 1 Micro Pin<span class="Sup">Â®</span>, 1 needle, 2 alcohol wipes, 1 gauze pad, and 1 adhesive bandage.
</p>
<div class="Figure">
<a name="f20"></a><img alt="PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ Lyophilized Powder Tray Lid
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0de49d64-3e18-494c-bf14-bc152247c798&amp;name=avo00-0015-20.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AVONEXÂ 		
					</strong><br><span class="contentTableReg">interferon beta-1a kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59627-001</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59627-001-03</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59627-001-04</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">PartÂ #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">1Â mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, PLASTIC </td>
<td class="formItem">10Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>AVONEXÂ 		
					</strong><br><span class="contentTableReg">interferon beta-1a injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>interferon beta-1a</strong> (interferon beta-1a) </td>
<td class="formItem">interferon beta-1a</td>
<td class="formItem">30Â ug Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Phosphate, Dibasic, Heptahydrate</strong></td>
<td class="formItem">5.7Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Phosphate, Monobasic, Monohydrate</strong></td>
<td class="formItem">1.2Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem">5.8Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Albumin (Human)</strong></td>
<td class="formItem">15Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103628</td>
<td class="formItem">05/17/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>WATERÂ 		
					</strong><br><span class="contentTableReg">water injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103628</td>
<td class="formItem">05/17/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103628</td>
<td class="formItem">05/17/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Biogen Idec MA Inc.
							(009492211)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d58e44ba-6047-4e8b-82e2-0656306ac75b</div>
<div>Set id: 0de49d64-3e18-494c-bf14-bc152247c798</div>
<div>Version: 9</div>
<div>Effective Time: 20120229</div>
</div>
</div>Â <div class="DistributorName">Biogen Idec MA Inc.</div></p>
</body></html>
